Ventura MV, Soriano RJ, Soria CD

Language: Spanish
References: 15
Page: 209-213
PDF size: 607.79 Kb.

ABSTRACT

A 28-year-old woman presented initially with urinary symptoms, diagnosed as uretheral lithiasis treated by surgery. After she had clinical data of peritoneal irritation and exploratory laparotomy was done. Then a retroperitoneal tumor of huge dimension was detected, subsequent to she had profuse bleeding and she died. In autopsy there is a 3.2 kg tumor, arising from the right adrenal area, is necrohemorrhagic, with infiltrative borders, that compress ipsilateral lung and kidney and invades the liver, pancreas, diaphragm and regional lymph nodes. Histologically the tumor is diffuse, with pleomorphic and undifferentiated cohesive cells, with eosinophil cytoplasm, more than five mitosis by fifty high power fields and broad necrosis areas. Immunohistochemically neoplastic cells are positive to alpha-inhibin, synaptophysin, Mart-1, vimentin and keratin. With the macroscopic, microscopic and immunophenotype features the final diagnosis is adrenocortical carcinoma. This neoplasm is rare, most frequent in young women, with bad prognosis and the final diagnosis is made by anatomopathological study.

REFERENCES

1. Wooten M, King D. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72: 3145-3155.

2. Didolkar M, Bescher A, Elias G, Moore R. Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patients. Cancer 1981; 47: 2153–2161.

3. Tartour E, Caillou B, Tenenbaum F et al. lmmunohistochemical Study of Adrenocortical Carcinoma. Predictive Value of the D11 monoclonal antibody. Cancer 1993; 72: 3296-303.

4. Slee P, Schaberg A, Van Brummelen P. Carcinoma of the adrenal cortex causing primary hyperaldosteronism. A case report and review of the literature. Cancer 1983; 51: 2341-2345.

5. Waichenberg B, Albergaria M, Mendonca B et al. Adrenocortical carcinoma clinical and laboratory observations. Cancer 2000; 88: 711–736.

6. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8: 163–169.

7. Stojadinovic A, Brennan M, Hoos A et al. Adrenocortical Adenoma and carcinoma: Histopathological and molecular comparative analysis. Mod Pathol 2003; 16: 742–751.

8. Stojadinovic A, Ghossein R, Hoos A et al. Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol 2002; 20: 941-950.

9. Fareau G, Vassilopoulou R. Diagnostic challenges in adrenocortical carcinoma: Recommendations for surveillance after surgical resection of selected adrenal nodules. Endocr Pract 2007; 13: 636-641.

10. Suzuki T, Sassano H, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol 2006; 17: 345- 354.

11. Sasano H, Suzuki T, Moriya T. Discerning malignancy in resected adrenocortical neoplasms. Endocr Pathol 2001; 12: 397-406.

12. Reincke M, Karl M, Travis W et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994; 78: 790–794.

13. Suzuki T, Sasano H, Nisikawa T et al. Discerning malignancy in human adrenocortical neoplasms: Utility of DNA flow cytometry and immunohistochemistry. Mod Pathol 1992; 5: 224-231.

14. Giordano T. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocr Pathol 2006; 17: 355-363.

15. Harrison L, Gaudin P, Brennan M. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999; 134: 181-185.